Overview
- The proposed settlement, which requires approval by a St. Louis court, would cover current and future eligible claims with payments spread over 21 years.
- Bayer will increase its Roundup litigation provisions by €4 billion to €11.8 billion.
- The company expects roughly €5 billion of disbursements in 2026 and projects a negative cash flow for the year, and it postponed its 2025 results release by one week.
- The agreements include no admission of liability, while plaintiffs have alleged links between glyphosate and non-Hodgkin lymphoma.
- The U.S. Supreme Court is reviewing Bayer’s appeal on claim admissibility with a decision expected by end-June, and Bayer’s shares rose about 7.35% in Frankfurt after the announcement.